- Morningstar Sustainalytics assessed about 15,000 companies across 42 industries in its 2026 ESG Risk Ratings.
- WuXi Biologics was placed in Sustainalytics' highest ESG tier as negligible risk, ranking in the top 1% globally in July 2025.
- As of December 31, 2025, WuXi Biologics supported 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
- The company employs over 13,000 people across China, the United States, Ireland, Germany and Singapore.
Recognition
WuXi Biologics was named Morningstar Sustainalytics’ Industry and Regional ESG Leader for 2026, marking the sixth consecutive year it has received this distinction.
Sustainalytics assessment
Morningstar Sustainalytics’ 2026 ESG Risk Ratings assessed about 15,000 companies across 42 industries; in July 2025 WuXi Biologics was placed in Sustainalytics’ highest ESG tier (negligible risk), ranking in the top 1% globally.
Other ESG ratings
The company has received multiple external ESG recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, listing in the Dow Jones Best‑in‑Class Indices, CDP “A List” status for Climate Change, Water Security and Supplier Engagement, inclusion in the FTSE4Good Index Series, an ISS ESG “Prime” designation, and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.
